NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS

(19)

(11)

EP 3 339 307 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	29.08.2018 Bulletin 2018/35

(43)	Date of publication:
	27.06.2018 Bulletin 2018/26

(21)	Application number: 16382627.4

(22)	Date of filing: 20.12.2016

(51)

International Patent Classification (IPC):

C07D 409/12^(2006.01)
C07D 217/02^(2006.01)
A61K 31/4725^(2006.01)
A61K 31/517^(2006.01)
A61P 29/00^(2006.01)

C07D 237/30^(2006.01)
A61K 31/4709^(2006.01)
A61K 31/502^(2006.01)
A61P 25/00^(2006.01)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA MD

(71)	Applicant: Laboratorios del Dr. Esteve, S.A.
	08041 Barcelona (ES)

(72)	Inventors:
	ALMANSA-ROSALES, Carmen 08022 Barcelona (ES) VIRGILI-BERNADÓ, Marina 08028 Barcelona (ES) ALONSO-XALMA, Monica 08028 Barcelona (ES)

(74)	Representative: Herrero & Asociados, S.L.
	Cedaceros, 1 28014 Madrid 28014 Madrid (ES)

(54)	NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS

(57) The present invention relates to new compounds of formula (I):

showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET).